ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Vanda To Pay $100m For Rights To MS The
ScripWho: Jemincare and Genentech What: The two companies have signed a licensing agreement around Jemincare’s androgen receptor degrader, JMKX002992. Why: The drug’s target is a confirmed disease dri